Drug intelligence / Profile preview

SFT-004

Development stage: Preclinical
Lead developer: invoX Pharma
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

**SFT-004** is an invoX Pharma respiratory drug-development asset listed for **asthma** and associated with the proprietary **Softhaler®** inhalation platform. The active pharmaceutical ingredient, molecular structure, pharmacologic class, and biological target have not been publicly disclosed in the available materials; therefore, a specific mechanism of action cannot be assigned. Softhaler® is a propellant-free, mechanically actuated soft-mist inhalation device designed to deliver liquid formulations to the lung. ([invoxpharma.com](https://invoxpharma.com/softhaler/))

Beyond the preview

Go deeper on SFT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFT-004.

Explore the full profile